Patents by Inventor Pedro Paz
Pedro Paz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240400700Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: May 16, 2024Publication date: December 5, 2024Applicant: Bayer AktiengesellschaftInventors: Sandra Berndt, Christian Bertling, Pascale Buchmann, Philipp Ellinger, Katharina Filarsky, Matyas Gorjanacz, Sabine Maria Hoff, Nikolaus Pawlowski, Helge Roider, Beatrix Stelte-Ludwig, Mark Trautwein, Ernst Weber, Uwe Gritzan, Oliver von Ahsen, Christian Votsmeier, Wiebke Maria Nadler, Patrick Jones, Pedro Paz, Su-Yi Tseng, Phaik Lyn Oh
-
Publication number: 20240376218Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: May 16, 2024Publication date: November 14, 2024Applicant: Bayer AktiengesellschaftInventors: Sandra Berndt, Christian Bertling, Pascale Buchmann, Philipp Ellinger, Katharina Filarsky, Matyas Gorjanacz, Sabine Maria Hoff, Nikolaus Pawlowski, Helge Roider, Beatrix Stelte-Ludwig, Mark Trautwein, Ernst Weber, Uwe Gritzan, Oliver von Ahsen, Christian Votsmeier, Wiebke Maria Nadler, Patrick Jones, Pedro Paz, Su-Yi Tseng, Phaik Lyn Oh
-
Publication number: 20240368280Abstract: The present invention provides antibodies, that bind to human CEACAM6 and are able to relieve CEACAM6-mediated immunosuppression, wherein said antibodies have reduced side-effects during treatment. The present invention further provides isolated nucleic acids encoding said antibodies and vectors comprising same, isolated cells expressing said antibodies, methods of producing said antibodies and pharmaceutical compositions and kits comprising said antibodies. Antibodies according to the present invention can be used to treat cancer and might be used to treat other disorders and conditions associated with the expression of the CEACAM6.Type: ApplicationFiled: September 1, 2022Publication date: November 7, 2024Inventors: Mark Trautwein, Jörg Willuda, Wolf-Dietrich Döcke, Pascale Buchmann, Rafael Carretero, Philipp Ellinger, Rienk Offringa, Franz Hendrik Nogai, Pedro Paz
-
Patent number: 12065497Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: GrantFiled: April 22, 2022Date of Patent: August 20, 2024Assignee: Bayer AktiengesellschaftInventors: Sandra Berndt, Christian Bertling, Pascale Buchmann, Philipp Ellinger, Katharina Filarsky, Matyas Gorjanacz, Sabine Hoff, Nikolaus Pawlowski, Helge Roider, Beatrix Stelte-Ludwig, Mark Trautwein, Ernst Weber, Uwe Gritzan, Oliver von Ahsen, Christian Votsmeier, Wiebke Maria Nadler, Patrick Jones, Pedro Paz, Su-Yi Tseng, Phaik Lyn Oh
-
Publication number: 20230250178Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: June 25, 2021Publication date: August 10, 2023Inventors: Sandra BERNDT, Katharina FILARSKY, Philipp ELLINGER, Beatrix STELTE-LUDWIG, Sabine HOFF, Helge ROIDER, Ernst WEBER, Mark TRAUTWEIN, Christian VOTSMEIER, Nikolaus PAWLOWSKI, Uwe GRITZAN, Pascale BUCHMANN, Christian BERTLING, Oliver VON AHSEN, Wiebke Maria NADLER, Su-Yi TSENG, Pedro PAZ, Phaik Lyn OH, Patrick JONES, Matyas GORJANACZ
-
Publication number: 20180185510Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.Type: ApplicationFiled: June 20, 2016Publication date: July 5, 2018Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Uwe GRITZAN, Pedro PAZ, Melanie FISCHER, Juergen FRANZ, Julian Marius GLÜCK, Stephan MÄRSCH, Beatrix STELTE-LUDWIG, Christoph MAHLERT, Ernst WEBER, Simone GREVEN, Sandra BERNDT
-
Publication number: 20150205911Abstract: A system, computer readable storage medium and method of predicting the immunogenicity of a peptide are provided. In certain cases the system includes: a) a model of a peptide, a model of a MHCII protein and a model of a T cell receptor; and b) an executable program for: (i) evaluating the strength of intermolecular interactions of a complex containing the peptide, the MHCII protein and the T cell receptor to provide a score that predicts the immunogenicity of the peptide; and (ii) outputting the score.Type: ApplicationFiled: March 14, 2013Publication date: July 23, 2015Inventors: Fred Jullien Aswad, Pedro Paz
-
Publication number: 20110263448Abstract: The present invention relates to a specific set of genes useful for determining the efficacy of a treatment against multiple sclerosis (MS). Further, the invention provides an array of these genes useful for evaluating efficacy of a MS treatment. Also provided are methods for evaluating efficacy of an MS treatment and a method for detecting neutralizing antibodies in patient response to interferon?-1B treatment of MS.Type: ApplicationFiled: September 16, 2009Publication date: October 27, 2011Applicant: BAYER HEALTHCARE LLCInventors: Edward Croze, Pedro Paz, Sharlene Velichko, Ken Yamaguchi, T. Charis Wagner